Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
Mario A. Eisenberger
Consultant or Advisory Role - Astellas Pharma; Astellas Pharma; Millennium; Millennium; Sanofi ; Sanofi
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Millennium; Millennium
Research Funding - Astellas Pharma; Astellas Pharma; Sanofi ; Sanofi ; Tokai; Tokai
Anne-Claire Hardy-Bessard
No relevant relationships to disclose
Loic Mourey
No relevant relationships to disclose
Paul N. Mainwaring
Consultant or Advisory Role - Advisory Role
Honoraria - Honararia
Daniel Ford
No relevant relationships to disclose
Jeremy David Shapiro
Consultant or Advisory Role - Merck
Joan Carles
No relevant relationships to disclose
Siobhan Ng
Consultant or Advisory Role - Sanofi
Thierry Gil
No relevant relationships to disclose
Boris Alekseev
No relevant relationships to disclose
Sergey Ivanov
No relevant relationships to disclose
Thomas Facchini
No relevant relationships to disclose
Eric Legouffe
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Oleg Apolikhin
No relevant relationships to disclose
Hardev S. Pandha
No relevant relationships to disclose
Aart Beeker
No relevant relationships to disclose
Oleg Karyakin
No relevant relationships to disclose
Wendy Zhang
Employment or Leadership Position - Sanofi
Mustapha Chadjaa
Employment or Leadership Position - Sanofi
Johann Sebastian De Bono
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi